Alimera Sciences (NASDAQ:ALIM – Get Rating) had its price target boosted by research analysts at HC Wainwright from $8.00 to $9.00 in a report issued on Thursday, The Fly reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 57.62% from the company’s current price.
Separately, StockNews.com initiated coverage on Alimera Sciences in a report on Sunday, July 24th. They set a “hold” rating for the company.
Alimera Sciences Trading Up 7.1 %
Shares of Alimera Sciences stock opened at $5.71 on Thursday. The stock has a fifty day simple moving average of $5.52 and a 200 day simple moving average of $5.23. Alimera Sciences has a 12-month low of $3.94 and a 12-month high of $9.79. The company has a market capitalization of $39.99 million, a P/E ratio of -5.65 and a beta of 1.46.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Alimera Sciences stock. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Alimera Sciences, Inc. (NASDAQ:ALIM – Get Rating) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 250,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,400,000. Healthcare of Ontario Pension Plan Trust Fund owned about 3.58% of Alimera Sciences at the end of the most recent reporting period. 40.97% of the stock is owned by institutional investors.
Alimera Sciences Company Profile
Alimera Sciences, Inc, a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.
- Get a free copy of the StockNews.com research report on Alimera Sciences (ALIM)
- Procter’s Earnings Start To Show Weakness In Q4
- MarketBeat: Week in Review 7/25 – 7/29
- The One Question You Have to Ask Before Investing in INTC Stock
- Home Depot: A Beautiful Boring Stock to Navigate a Bear Market
- Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.